Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.

Brain barriers in gliomas’ CNS parenchyma compartments restrict immune-cell and immune-mediator access, shielding tumors from immune detection and limiting immunotherapy efficacy.

• Why it matters: Glioma immunotherapies remain limited despite advances elsewhere, and this gap is linked to CNS immune privilege and barrier-controlled immune surveillance.
• What they did: The review synthesizes evidence that brain barriers compartmentalize immune access, directing surveillance to subarachnoid and perivascular spaces, while gliomas remodel barrier functions for immune evasion.
• The result: Incorporating brain barrier function into immunotherapy strategy and clinical trial design is proposed to improve immune surveillance and enhance immunotherapy responses in patients with brain tumors.

AI summary of the abstract · may contain errors · not medical advice · read the paper.